Skip to content
Search

Latest Stories

Women Breaking Barriers: GPhC Chair Gisela Abbam wins Novi award

Gisela Abbam, chair of GPhC, honoured with a prestigious Novi Award
Gisela winning an award

The Novi Awards 2024 celebrated extraordinary women transforming industries across the UK and beyond

Gisela Abbam, chair of the General Pharmaceutical Council (GPhC), has been honoured with a prestigious Novi Award in recognition of her outstanding leadership, innovation, and entrepreneurship.

She received the award in the 'Women on Boards' category during a ceremony held on November 24.


With the theme “Women Breaking Barriers,” the Novi Awards 2024 celebrated extraordinary women transforming industries across the UK and beyond.

On receiving the award, Abbam said: “I’m delighted to be amongst this year’s winners who have shown that it is possible for women of all backgrounds to achieve great things across all different sectors.

“I believe that being a leader is about being an advocate – not only to drive change, but also to support and inspire the people around you.

“It is an honour to be recognised through this award.”

GPhC chief executive Duncan Rudkin, congratulated Gisela on winning the “well-deserved award.”

“Gisela is passionate about improving access and equality in health and that is evident in her work as Chair at the GPhC,” he said.

He went on to say that she is a “fantastic role model and a worthy winner.”

The star-studded ceremony at The Londoner brought together influential leaders, entrepreneurs, and changemakers, featuring crucial discussions on pressing issues facing women in business, including the severe underfunding of women’s healthcare, and fostering truly inclusive workplaces.

Griselda Togobo, founder of the Novi Awards, said: “Novi represents more than recognition – it’s a movement to drive real change for women in business.”

“This year’s winners exemplify the breakthrough leadership and innovation that’s possible when we champion diverse voices and perspectives.”

The event highlighted 83 exceptional nominees across 16 categories who are reshaping the future of business and technology.

“This year’s winners and nominees aren’t just breaking barriers – they’re completely redefining what’s possible.

“Their success stories prove that when we invest in women’s leadership, entire industries transform for the better,” added Togobo.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less